Current and Future Treatment of Peanut Allergy

Brian P Vickery; Motohiro Ebisawa; Wayne G Shreffler; Robert A Wood

doi:10.1016/j.jaip.2018.11.049

Current and Future Treatment of Peanut Allergy

J Allergy Clin Immunol Pract. 2019 Feb;7(2):357-365. doi: 10.1016/j.jaip.2018.11.049.

Authors

Brian P Vickery¹, Motohiro Ebisawa², Wayne G Shreffler³, Robert A Wood⁴

Affiliations

¹ Emory University School of Medicine, Atlanta, Ga. Electronic address: bpvicke@emory.edu.
² Sagamihara National Hospital, Sagamihara, Japan.
³ Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
⁴ Johns Hopkins University School of Medicine, Baltimore, Md.

PMID: 30717866
DOI: 10.1016/j.jaip.2018.11.049

Abstract

Based on productive translational research programs conducted over the last 20 years, the clinical landscape of peanut allergy is now rapidly changing. In this review, we review data from recent trials of investigational peanut oral and epicutaneous immunotherapies, explore the pipeline of novel therapies in early development, and identify future research needs and priorities.

Keywords: Anaphylaxis; Desensitization; Peanut allergy; Quality of life; Sustained unresponsiveness; Tolerance.

Publication types

Review

MeSH terms

Biomedical Research / trends
Desensitization, Immunologic
Forecasting
Humans
Peanut Hypersensitivity / therapy*